Nonionic surfactant based thymoquinone loaded nanoproniosomal formulation: in vitro physicochemical evaluation and in vivo hepatoprotective efficacy

References

• Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf. 2001; 24:483–490.
   PubMed Web of Science ®Google Scholar
• Zimmerman H. Drug-induced liver disease. In: Schiff E, Sorell M, Madding W, editors. Schiff’s diseases of the liver. 8th ed. Philadelphia: Lippencourt Raven; 1999. p. 973–1064.
   Google Scholar
• Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis. 2002; 6:755–774.
   PubMedGoogle Scholar
• Mollazadeh H, Hosseinzadeh H. The protective effect of Nigella sativa against liver injury: a review. Iran J Basic Med Sci. 2014;17:958–966.
   PubMed Web of Science ®Google Scholar
• Salem ML. Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Int Immunopharmacol. 2005; 5:1749–1770.
   PubMed Web of Science ®Google Scholar
• Woo CC, Loo SY, Gee V, et al. Anticancer activity of thymoquinone in breast cancer cells: possible involvement of PPAR-γ pathway. Biochem Pharmacol. 2011;82:464–475.
   PubMed Web of Science ®Google Scholar
• Badr G, Mohany M, Abu-Tarboush F. Thymoquinone decreases F-actin polymerization and the proliferation of human multiple myeloma cells by suppressing STAT3 phosphorylation and Bcl2/Bcl-XL expression. Lipids Health Dis. 2011a;10:1–8.
   Web of Science ®Google Scholar
• Badr G, Alwasel S, Ebaid H, et al. Perinatal supplementation with thymoquinone improves diabetic complications and T cell immune responses in rat offspring. Cell Immunol. 2011b;267:133–140.
   PubMed Web of Science ®Google Scholar
• Bouchra M, Robert D, Moulay F, et al. Nigella sativa inhibits intestinal glucose absorption and improvesglucose tolerance in rats. J Ethnopharmacol. 2009;21:419–424.
   Google Scholar
• Badr G, MH, Mahmoud K, Farhat H, Waly OZ, et al. Maternal supplementation of diabetic mice with thymoquinone protects their offspring from abnormal obesity and diabetes by modulating their lipid profile and free radical production and restoring lymphocyte proliferation via PI3K/AKT signaling. Lipids Health Dis. 2003;12:1–10.
   Google Scholar
• Ragheb A, Attia A, Eldin WOS, et al. The protective effect of thymoquinone, an anti-oxidant and anti-inflammatory agent, against renal injury: a review. Saudi J Kidney Dis Transpl. 2009;20:741–752.
   PubMedGoogle Scholar
• Ali BH, Blunden G. Pharmacological and toxicological properties of Nigella sativa. Phytother Res. 2003;17:299–305.
   PubMed Web of Science ®Google Scholar
• Nagi M, Mansour M. Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: a possible mechanism of protection. Pharmacol Res. 2000; 41:283–289.
   PubMed Web of Science ®Google Scholar
• Mansour MA. Protective effects of thymoquinone and desferrioxamine against hepatotoxicity of carbon tetrachloride in mice. Life Sci. 2000;66:2583–2591.
   PubMed Web of Science ®Google Scholar
• Badary OA. Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice. J Ethnopharmacol. 1999;67:135–142.
   PubMed Web of Science ®Google Scholar
• Aboul-Ela EI. Cytogenetic studies on Nigella sativa seeds extract and thymoquinone on mouse cells infected with schistosomiasis using karyotyping. Mutat Res. 2002; 516:11–17.
   PubMed Web of Science ®Google Scholar
• Mohany M, El-Feki M, Refaat I, et al. Thymoquinone ameliorates the immunological and histological changes induced by exposure to imidacloprid insecticide. J Toxicol Sci. 2012; 37:1–11.
   PubMed Web of Science ®Google Scholar
• Alkharfy KM, Ahmad A, Khan RM, et al. Pharmacokinetic plasma behaviors of intravenous and oral bioavailability of thymoquinone in a rabbit model. Eur J Drug Metab Pharmacokinet. 2015;40:319–323.
   PubMed Web of Science ®Google Scholar
• Lobenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm. 2000;50:3–12.
   PubMed Web of Science ®Google Scholar
• Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29:278–277.
   PubMed Web of Science ®Google Scholar
• Porter CJH, Trevaskis NL, WN, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6:231–248.
   PubMed Web of Science ®Google Scholar
• Nasr M. In vitro and in vivo evaluation of proniosomes containing celecoxib for oral administration. AAPS PharmSciTech. 2010;11:85–89.
   PubMed Web of Science ®Google Scholar
• Jamal M, Imam SS, Aqil M, et al. Transdermal potential and anti-arthritic efficacy of ursolic acid from niosomal gel systems. Int Immunopharmacol. 2015;29:361–369.
   PubMed Web of Science ®Google Scholar
• Imam SS, Aqil M, Akhtar M, et al. Formulation by design-based proniosome for accentuated transdermal delivery of risperidone: in vitro characterization and in vivo pharmacokinetic study. Drug Deliv. 2015;22:1059–1070.
   PubMed Web of Science ®Google Scholar
• Prasad PS, Imam SS, Aqil M, et al. QbD-based carbopoltransgel formulation: characterization, pharmacokinetic assessment and therapeutic efficacy in diabetes. Drug Deliv. 2016;23:1047–1056.
   PubMed Web of Science ®Google Scholar
• Abidin L, Mujeeb M, Imam SS, et al. Enhanced transdermal delivery of luteolin via non-ionic surfactant-based vesicle: quality evaluation and anti-arthritic assessment. Drug Deliv. 2016;23:1069–1074.
   Web of Science ®Google Scholar
• Moghddam SSM, Ahad A, Aqil M, et al. Formulation and optimization of niosomes for topical diacerein delivery using 3-factor, 3-level Box-Behnken design for the management of psoriasis. Mater Sci Eng C. 2016;69:789–797.
   PubMed Web of Science ®Google Scholar
• Akhtar M, Imam SS, Ahmad MA, et al. Neuroprotective study of Nigella sativa-loaded oral provesicular lipid formulation: in vitro and ex vivo study. Drug Deliv. 2014;21:487–494.
   PubMed Web of Science ®Google Scholar
• Alsarra IA, Bosella AA, Ahmad SM, et al. Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur J Pharm Biopharm. 2005;59:485–490.
   PubMed Web of Science ®Google Scholar
• Szuts A, Budai-Szucs M, Eros I, et al. Study of gel-forming properties of sucrose esters for thermosensitive drug delivery systems. Int J Pharm. 2010;383:132–137.
   PubMed Web of Science ®Google Scholar
• All C, Ertan B, Ergul BK, et al. N-acetylcysteine ameliorates methotrexate-induced oxidative liver damage in rats. Med Sci Monit. 2006;12: BR247–BR248.
   Web of Science ®Google Scholar
• Ohkawa H, Ohishi N, Tagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351–358.
   PubMed Web of Science ®Google Scholar
• Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82:70–77.
   PubMed Web of Science ®Google Scholar
• Marklund SL. Superoxide dismutase isoenzymes in tissues and plasma from New Zealand black mice, nude mice and normal BALB/c mice. Mutat Res. 1985;148:129–134.
   PubMed Web of Science ®Google Scholar
• Clairborne A. Catalase activity. In: Greenwold RA, editor) Handbook of methods for oxygen radical research. Boca Raton (FL): CRC Press; 1985:283–284.
   Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–275.
   PubMed Web of Science ®Google Scholar
• Hartez PH. Simultaneous histopathologic fixation and gross demonstration of calcification. Am J ClinPathol. 1947;17:750–755.
   Web of Science ®Google Scholar
• Rogerson A, Cummings J, Florence AT. Adriamycin-loaded niosomes: drug entrapment, stability and release. J Microencapsul. 1987;4:321–328.
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. Liposome technology. 2nd ed. Boca Raton (FL): CRC Press; 1993.
   Google Scholar
• Touitou E, Junginger HE, Weiner ND, et al. Liposomes as carriers for topical and transdermal delivery. J Pharm Sci. 1994;83:1189–1203.
   PubMed Web of Science ®Google Scholar
• Ogiso T, Niinaka N, Iwaki M. Mechanism for enhancement effect of lipid disperse system on percutaneous absorption. J Pharm Sci. 1996;85:57–64.
   PubMed Web of Science ®Google Scholar
• Kulkarni SB, Betageri GV, Singh M. Factors affecting microencapsulation of drugs in liposomes. J Microencapsul. 1995;12:229–246.
   PubMed Web of Science ®Google Scholar
• Hiremath PS, Soppimath KS, Betagiri GV. Proliposomes of exemestane for improved oral delivery: formulation and in vitro evaluation using PAMPA, Caco-2 and rat intestine. Int J Pharm. 2009;380:96–104.
   PubMed Web of Science ®Google Scholar
• Fu Y, Zheng S, Lin J, et al. Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol Pharmacol. 2008;73:399–409.
   PubMed Web of Science ®Google Scholar
• Rosen HR, Keeffe EB. Laboratory evaluation of the patients with signs and symptoms of liver disease. In: Brandt LJ, editor. Clinical practice of gastroenterology. Philadelphia: Livingstone; 2000. p. 812–820.
   Google Scholar
• Jahovic N, Cevik H, Sehirli AO, et al. Melatonin prevents methotraxate-induced hepatorenal oxidative injury in rats. J Pineal Res. 2003;34:282–287.
   PubMed Web of Science ®Google Scholar
• Cighetti G, Duca L, Bortone L, et al. Oxidative status and malondialdehyde in β-thalassaemia patients. Eur J Clin Invest. 2002;32:55–60.
   PubMed Web of Science ®Google Scholar
• Sener G, Eksioglu-Demiralp E, Cetiner M, et al. L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Cell Biol Toxicol. 2006;22:47–60.
   PubMed Web of Science ®Google Scholar
• Kanter M, Coskun O, Budancamanak M. Hepatoprotective effects of Nigella sativa L and Urticadioica L on lipid peroxidation, antioxidant enzyme systems and liver enzymes in carbon tetrachloride-treated rats. World J Gastroenterol. 2005;42:6684-8.
   Google Scholar
• Hersh EM, Wong VG, Henderson ES, et al. Hepatotoxic effects of methotrexate. Cancer. 1966;19:600–606.
   PubMed Web of Science ®Google Scholar
• Hall PD, Jenner MA, Ahern MJ. Hepatotoxicity in a rat model caused by orally administered methotrexate. Hepatology. 1991;14:906–910.
   PubMed Web of Science ®Google Scholar
• Babiak RM, Campello AP, Carnieri EG, et al. Methotrexate: pentose cycle and oxidative stress. Cell Biochem Funct. 1998;16:283–293.
   PubMed Web of Science ®Google Scholar
• Ozogula B, Kisaoglua A, Turanb MI, et al. The effect of mirtazapine on methotrexate-induced toxicity in rat liver. Sci Asia. 2013;39:356–362.
   Web of Science ®Google Scholar
• Hemeida RA, Mohafez OM. Curcumin attenuates methotraxate-induced hepatic oxidative damage in rats. J Egypt Natl Canc Inst. 2008;20:141–148.
   PubMedGoogle Scholar
• Aycan IO, Tufek A, Tokgoz O, et al. Thymoquinone treatment against acetaminophen-induced hepatotoxicity in rats. Int J Surg. 2014;12:213–218.
   PubMed Web of Science ®Google Scholar
• Nili-Ahmadabadi A, Tavakoli F, Hasanzadeh GR, et al. Protective effect of pretreatment with thymoquinone against Aflatoxin B1 induced liver toxicity in mice. Daru. 2011;19:282–287.
   PubMed Web of Science ®Google Scholar